STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

Valentina Cannone; Mark Ledwidge; Chris Watson; Paul M McKie; John C Burnett; Kenneth McDonald

doi:10.1016/j.jacbts.2021.05.001

STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

Valentina Cannone
, Mark Ledwidge
, Chris Watson
, Paul M McKie
, John C Burnett
, Kenneth McDonald

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

120 Downloads (Pure)

Abstract

B-type natriuretic peptide (BNP) possesses blood-pressure-lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.

Original language	English
Pages (from-to)	497-504
Number of pages	8
Journal	JACC: Basic to Translational Science
Volume	6
Issue number	6
DOIs	https://doi.org/10.1016/j.jacbts.2021.05.001
Publication status	Published - 16 Jun 2021

Bibliographical note

Access to Document

10.1016/j.jacbts.2021.05.001Licence: CC BY-NC-ND

STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure
Copyright 2021 the authors. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Final published version, 743 KBLicence: CC BY-NC-ND

Cite this

@article{8bc70e679b05416a9d7a951f6037afbb,

title = "STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure",

abstract = "B-type natriuretic peptide (BNP) possesses blood-pressure-lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.",

author = "Valentina Cannone and Mark Ledwidge and Chris Watson and McKie, \{Paul M\} and Burnett, \{John C\} and Kenneth McDonald",

note = "{\textcopyright} 2021 The Authors.",

year = "2021",

month = jun,

day = "16",

doi = "10.1016/j.jacbts.2021.05.001",

language = "English",

volume = "6",

pages = "497--504",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

AU - Cannone, Valentina

AU - Ledwidge, Mark

AU - Watson, Chris

AU - McKie, Paul M

AU - Burnett, John C

AU - McDonald, Kenneth

PY - 2021/6/16

Y1 - 2021/6/16

N2 - B-type natriuretic peptide (BNP) possesses blood-pressure-lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.

AB - B-type natriuretic peptide (BNP) possesses blood-pressure-lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.

U2 - 10.1016/j.jacbts.2021.05.001

DO - 10.1016/j.jacbts.2021.05.001

M3 - Article

C2 - 34222720

SN - 2452-302X

VL - 6

SP - 497

EP - 504

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 6

ER -

STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this